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A  big  challenge  in pharmacology  is  the  understanding  of  the  underlying  mechanisms  that  cause  drug-
induced  adverse  reactions  (ADRs),  which  are  in  some  cases  similar  to each  other  regardless  of  different
drug  indications,  and  are  in  other  cases  different  regardless  of  same  drug  indications.  The  FDA  Adverse
Event  Reporting  System  (FAERS)  provides  a valuable  resource  for pharmacoepidemiology,  the study  of
the  uses  and  the  effects  of  drugs  in  large  human  population.  However,  FAERS  is  a spontaneous  reporting
system  that inevitably  contains  noise  that  deviates  the  application  of  conventional  clustering  approaches.
By  performing  a  biclustering  analysis  on the  FAERS  data  we identiﬁed  163  biclusters  of drug-induced
adverse  reactions,  counting  for  691  ADRs  and 240  drugs  in  total,  where  the  number  of ADR  occurrences
are  consistently  high  across  the  associated  drugs.  Medically  similar  ADRs  are  derived  from  several  distinct
indications  for  use  in  the majority  (145/163  =  88%)  of the  biclusters,  which  enabled  us to interpret  the
underlying  mechanisms  that  lead  to similar  ADRs.  Furthermore,  we compared  the  biclusters  that  contain
same  drugs  but  different  ADRs,  ﬁnding  the  cases  where  the  populations  of  the  patients  were  different
in  terms  of  age,  sex,  and  body  weight.  We  applied  a  biclustering  approach  to catalogue  the relationship
between  drugs  and  adverse  reactions  from  a large  FAERS  data  set,  and  demonstrated  a systematic  way
to  uncover  the  cases  different  drug  administrations  resulted  in  similar  adverse  reactions,  and  the  same
reacti
access drug  can  cause  different  
©  2014  Elsevier  Ltd.  
. Introduction
Adverse drug reactions (ADRs) are one of the main causes of
orbidity and mortality worldwide (Giacomini et al., 2007). Since
ot all ADRs are detected during drug development processes or
linical trials, many of them become a serious public health concern
fter the drugs are launched in the market. Post-marketed drugs,
owever, are continuously surveilled for adverse events and med-
cation errors by regulatory agencies, pharmaceutical companies,
nd hospitals.
A  big challenge in pharmacology is the understanding of the
nderlying mechanisms that cause these ADRs, which are in some
ases similar to each other regardless of different drug indications.
or example, a number of psychiatric disorders are expressed as a
esult of taking anti-psychotics, but some are also reported as side
Open ffects of unrelated drugs such as tamiful, an anti-inﬂuenza drug. As
nother example, varenicline, used to treat smoking addiction, and
abapentin, used to relieve neuropathic pain, both have showed
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oro@kuicr.kyoto-u.ac.jp (Y. Noro), kot@kuicr.kyoto-u.ac.jp (M.  Kotera),
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Open access under CC BY-NC-ND license.ons  dependent  on  the  patients’  conditions.
risks of causing severe adverse events such as suicidal behaviors.
It is suggested the similar ADRs by different drugs are the result of
their common mechanisms.
In  other cases, even when the same drug is used, the expres-
sion of ADRs varies from patients to patients. Types and severity of
ADRs may  vary depending on the patients’ physiological conditions
such as age, sex, body weight, as well as their health states, and
such information is provided in drug package inserts. Kuhn et al.
(2010) collected drug side-effects by text-mining package inserts
of marketed drugs, and listed them in the SIDER database. However,
their approach has not yet covered these variabilities in the popu-
lation of drug responses. In order to design personalized medicines,
it is important to divide populations of patients according to their
reaction expression patterns and characterize the populations with
patients physiological backgrounds.
Spontaneous ADR reporting systems monitor unexpected drug
outcomes over a large population of patients, and are extremely
valuable for pharmacoepidemiology, the study of the effects of
drugs focusing on the variabilities of drug responses. The FDA
Adverse Event Reporting System (FAERS) (http://www.fda.gov/
under CC BY-NC-ND license.Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/
AdverseDrugEffects/default.htm)  has collected incidence of ADRs
in  the form of adverse event reports, where each report lists ADRs
and the associated drugs along with the drug indications for use
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the patients’ disease symptoms for which the drugs are pre-
cribed). An event report also provides the patients’ demographic
ata. These resources provide us with proﬁles of ADRs and drugs
rom which knowledge may  be mined to help characterize the
dverse events.
A  number of research studied the FAERS data. For example,
ate and Evans (2009) and Harpaz et al. (2013) detected possi-
le relationships between ADRs and drugs that are unknown or
ncompletely documented in drug package inserts, but they did
ot systematically take the effects of the drug indications into con-
ideration. Other studies detected ADR-drug pairs in consideration
f only particular indications, e.g., anticoagulants (Tamura et al.,
012). Tatonetti et al. (2012) used information on drug indications
r the patients’ physiological data to improve the detection method,
hereas they did not consider the varieties of indications that cause
he same ADR in a mechanistic point of view. In this study, we con-
ucted a comprehensive investigation of the relationships between
DRs and the drug indications to identify drug administration pat-
erns which lead to certain groups of ADRs, aiming at inferring the
ommon mechanisms of reaction occurrences.
Clustering ADRs from the FAERS event reports may  give us an
nference of the common characteristics of ADR incidences. How-
ver, in contrast to the manually curated data such as drug package
nserts, the spontaneous reporting system such as FAERS contains
ore noise, which deviates the application of conventional one-
ay clustering approaches. Speciﬁcally, considering a subset of
rugs, rather than using all drugs, may  help collecting ADRs whose
vent frequency proﬁles show high correlations. Accordingly, we
pplied a biclustering approach to the event frequency data from
AERS to extract clusters of drugs and ADRs in this study. A biclus-
ering method, one of data mining approaches, is a useful tool to
xtract knowledge from such noisy data. The advantage of biclus-
ering over one-way clustering is that it allows to focus on a subset
f conditions over which features of correlated proﬁles are grouped
n a cluster, while omitting other conditions of less correlation.
It  was shown that our biclustering approach extracted clusters
ith different but possibly overlapping drugs and ADRs. Then we
haracterized the extracted clusters in the points of drug indica-
ions, using event reports in each cluster to infer how the drugs
ith different indications can cause the incidence of medically
imilar ADRs. Characterizing the extracted adverse event groups
evealed the differences in patients’ populations (e.g., age, sex, and
ody weights) which showed expressions of different ADRs from
he same drugs. Our ﬁndings may  help understanding how an ADR
an occur from unrelated drugs and how the patients’ physiological
ackgrounds may  be an important factor for increased risk of the
DR.
. Results and discussion
.1.  Extraction of drug-induced adverse reaction clusters
In  order to ﬁnd the biclusters of ADRs and associated drugs, we
btained 425 273 adverse event reports from the FAERS, which con-
ained the total of 5802 ADRs and 1909 drugs. We  coded the drugs
n “D numbers”, unique identiﬁcation numbers of drug entries in
he KEGG DRUG database (Kanehisa et al., 2012), where drugs are
haracterized in a number of annotating systems including the
natomical Therapeutic Chemical (ATC) classiﬁcation system, and
re cross-liked by LinkDB (Fujibuchi et al., 1998) to other pharma-
ological databases such as DrugBank (Knox et al., 2011), SIDER,
nd DailyMed (http://dailymed.nlm.nih.gov/dailymed/about.cfm).
his yielded 1374 D numbers. Medically similar ADR terms
ere grouped using the MedDRA dictionary at the “High Level
erms (HLTs)”, which yielded 1317 HLTs. Based on the data wey and Chemistry 50 (2014) 50–59 51
constructed  an event report frequency matrix whose rows are the
ADRs and columns are the drugs. Then we performed an unsuper-
vised biclustering to identify subsets of the ADRs (referred to as
“REACs” hereafter) and subsets of drugs (referred to as “DRUGs”
hereafter), where the frequencies of the REACs are consistently
high across the DRUGs, using the Iterative Signature Algorithm
(ISA) (Ihmels et al., 2004). In general, biclustering approaches pose
a tradeoff between the overall coverage of row and column mem-
bers, and the stringency of the extracted biclusters. Therefore, we
optimized the bicluster extraction by setting a parameter range for
the ISA workﬂow, following the strategy employed by Iskar et al.
(2013). Detailed optimization process is described in Section 4.
As a result, we extracted 163 biclusters (or “clusters” hereafter)
containing 691 REACs and 240 DRUGs, and 182 000 event reports
(43% of all event reports counted in the matrix) in total. Some
DRUGs and REACs appeared in more than one cluster. Fig. 1 shows
the distribution of the FAERS adverse report entities, in which the
ADRs were classiﬁed by the MedDRA “System Organ Class (SOC)”
level, and the drugs were classiﬁed by the ATC anatomical level.
Although the number of REACs and DRUGs extracted in the 163
clusters is not large, biclusering process retained the variations of
the classiﬁcations. Fig. 2 shows the number of REACs and DRUGs
extracted in each of the 163 clusters. Detailed information of the
cluster entities are found in Table S1.
2.2. Referring for known ADRs in drug package inserts
In  order to check how many REACs in the 163 clusters are docu-
mented in drug package inserts, we  referred the SIDER database. In
the original data matrix, 80 019 drug-ADR pairs appeared at least in
one event report, of which 34 315 (43 %) were listed in SIDER. In the
163 clusters, the number of drug-ADR pairs that were extracted at
least in one cluster was  5159, of which 2481 pairs (48%) were listed
in SIDER. This points out that the biclustering did not signiﬁcantly
affect the ratio of ADRs written in drug package inserts. It is also sug-
gested that, even though the spontaneous ADR reports may  contain
many noises, the 2678 drug-ADR pairs that were found in the 163
clusters but not in SIDER may  be worth investigating in order to
enhance drug package inserts.
2.3. Characterization of drug-induced adverse reaction clusters
by  related indication proﬁles
Each  resulting cluster consists of REACs whose overall event
report frequencies were consistently high across associated DRUGs
in the cluster. Studying REACs and DRUGs within each cluster is
expected to reveal physiological or molecular regulations com-
mon to take place in the expressions of REACs in the cluster. First
we checked whether REACs in a cluster are medically similar to
each other. Since REACs are written in the MedDRA HLT level, they
were mapped to the HLGT level, one level higher to the HLT in the
MedDRA hierarchy. Medical similarity of REACs was measured by
how inequally the REACs were distributed across different HLGT
terms, using the Gini coefﬁcient (see Section 4). Gini coefﬁcient
measures the inequality among values of a frequency distribu-
tion, and high Gini coefﬁcient represents high homogeneity in the
population. Fig. 3 (right histogram) shows the distribution of 163
clusters as a function of Gini coefﬁcient. In clusters with higher
Gini coefﬁcients, REACs were inequally distributed over a group of
HLGTs, i.e., the majority of REACs was categorized only in particu-
lar HLGT(s), and were not categorized in any other HLGTs, which
means the REACs in these clusters showed medical similarity in the
MedDRA hierarchical classiﬁcation. Similar REACs may  be derived
from administrations of unrelated drugs. In order to measure the
degree of variation in DRUGs we  constructed drug indication (INDI,
hereafter) proﬁles within each cluster. The drug INDI proﬁles are
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Fig. 1. ATC classiﬁcation of drugs and MedDRA classiﬁcation of adverse reactions in the original FAERS data and in 163 identiﬁed clusters. Left: The number of drugs was
counted for each category of the ATC anatomical level (ﬁrst level of the ATC hierarchy). Right: The number of ADRs was counted for each of the MedDRA “System organ class”
( the original 1317 × 1374 matrix (blue) and the 163 identiﬁed biclusters (red). Although
b rsity in the ATC and MedDRA classiﬁcations. (For interpretation of the references to color
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lso found in Table S1. For each pair of drugs in a cluster, we  cal-
ulated the Pearson’s correlation coefﬁcient of their INDI proﬁles,
nd averaged over all drug pairs within the cluster. In Fig. 3 (top
istogram), the 145 clusters out of 163 (89%) show Pearson’s corre-
ation coefﬁcients less than 0.5, indicating that they had relatively
igh variation in DRUG INDIs. In addition, Fig. 3 (scatter plot in
he center) shows that these 145 clusters are separated from the
emaining 18 clusters. They represent high similarity in REACs and
igh variation in DRUG INDIs, which supports the tendency that
edically similar ADRs can occur as a result of administrations of
rugs with different indications for use.
ig. 2. The identiﬁed 163 biclusters are plotted for the number of DRUGs and REACs.
etailed descriptions of DRUGs and REACs in each of the biclusters are found in Table
1.
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Fig. 3. Intra-cluster variation in DRUG and REACs. For each of the 163 clusters, the
degree of similarity in REACs and the degree of variation in DRUGs were measured.
Top  histogram: Distributions of Pearson’s correlation coefﬁcients of DRUG indica-
tions (INDIs) calculated to measure the variation of DRUGs in each of the 163 clusters.
145 out of 163 clusters (89%) showed Pearson’s correlation coefﬁcients less than
0.5, indicating that the 145 clusters had relatively high variation in DRUGs. Right
histogram: Distributions of Gini coefﬁcients calculated to measure the medical sim-
ilarity in REACs in each of the 163 clusters. Higher Gini coefﬁcient values represent
higher  similarity of REACs within a cluster. Center: The 163 clusters are plotted for
Pearson’s correlation coefﬁcients and Gini coefﬁcients. 145 clusters (circles) were
separated from the remaining 18 clusters (triangles) in the plot, showing high vari-
ation in DRUGs. These 145 clusters possessed REACs that were medically similar,
but  variable DRUGs in terms of their INDI proﬁles.
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Table  1
Comparison of REACs and indication proﬁles for extracted drugs in Clusters 17, 29, and 30.
Cluster ID REACs DRUGs Indications
17 Gastrointestinal haemorrhages Type 1:
Non-site speciﬁc gastrointestinal
haemorrhages
Warfarin  (D00564) Supraventricular arrhythmias
REAC  Nervous system haemorrhagic
disorders
Peripheral embolism and thrombosis
0.6987666 Cerebral injuries Cardiac valve therapeutic procedures
Traumatic central nervous system
haemorrhages
Type 2:
DRUG Gastric and oesophageal haemorrhages Rofecoxib (D00568) Arthropathies
0.1155793 Celecoxib (D00567) Osteoarthropathies
Musculoskeletal and connective tissue pain and discomfort
Type 3:
Aspirin (D00109) Coronary necrosis and vascular insufﬁciency
Clopidogrel  (D07729) Cerebrovascular and spinal necrosis and vascular insufﬁciency
Prophylactic procedures
29  Partial vision loss Type 1:
Retinal structural change, deposit and
degeneration
Bevacizumab (D06409) Retinal structural change, deposit and degeneration
REAC  Ocular haemorrhagic disorders Ranibizumab (D05697) Ocular vascular disorders
0.5255139  Eye injuries Verteporﬁn (D01162) Choroid and vitreous haemorrhages and vascular
disorders
Choroid  and vitreous haemorrhages
and  vascular disorders
Type 2:
DRUG Sildenaﬁl (D02229) Sexual arousal disorders
0.1164479  General signs and symptoms
Type  3:
Interferon beta-1a (D04554) Multiple sclerosis acute and progressive
Type  4:
Etanercept (D00742) Rheumatoid arthritis and associated conditions
Psoriatic conditions
30  Dyskinesias and movement disorders Type 1:
Dystonias Aripiprazole (D01164) Schizophrenia
REAC  Body temperature altered Haloperidol (D00136) Bipolar disorders
0.9108681  Parkinson’s disease and parkinsonism Quetiapine (D00458) Psychotic disorder
Eyelid movement disorders Ziprasidone mesylate (D02100) General signs and symptoms
DRUG  Decreased physical activity levels Ziprasidone hydrochloride (D01939) Schizoaffective and schizophreniform disorders
0.3415874 Risperidone (D00426) Depressive disorders
Type 2:
Atomoxetine (D02574) Attention deﬁcit and disruptive behaviour disorders
In the ﬁrst column, values under “REAC” and “DRUG” are Gini coefﬁcients for REACs, and Pearson’s correlation coefﬁcients for DRUGs, respectively. The second column lists
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olumn lists the Indications for the different types of DRUGs.
The 145 clusters can be, therefore, interpreted as the catalogues
f different drug administration patterns which can lead to the
roup of medically similar ADRs. Here, by giving three clusters as
xamples (Table 1 and Fig. 4), we address how medically similar
EACs can occur as a result of administrating the associated DRUGs
ith different INDIs. In cluster 17, gastrointestinal and nervous sys-
em haemorrhages were two major REACs, which were associated
ith DRUGs of roughly three types of INDIs. Type 1: Warfarin is
n anticoagulant (vitamin-K-epoxide reductase inhibitor), mainly
ndicated in this cluster for the treatment of “supraventricular
rrhythmias”. Type 2: Rofecoxib and celecoxib are nonsteroidal
nti-inﬂammatory drugs (NSAIDs) (selective cyclooxygenase-2
COX-2) inhibitors), that had indications for “arthropathies”,
osteoarthropathies”, and other musculoskeletal pain. Type 3:
spirin and clopidogrel were indicated for “central nervous sys-
em haemorrhages and cerebrovascular accidents” and “coronary
ecrosis and vascular insufﬁciency”. They have additional efﬁcacies.
spirin is an antithrombotic agent, but is also a nonsteroidal
nti-inﬂammatory drug (NSAIDs) (nonselective cyclooxygenase-1
COX-1) and cyclooxygenase-2 (COX-2) inhibitor). Clopidogrel
s also an anticoagulant but targets different receptor (P2Y12
eceptor antagonist). The risk of haemorrhage in warfarin use has
een suspicious to incomplete regulations of warfarin dose (Ageno
t al., 2012; Lam et al., 2013). The risk of haemorrhages have been
uggested and reported for aspirin, clopidogrel, and a numberhich are divided in distinct types according to their indication proﬁles. The fourth
of  NSAIDs (Tamura et al., 2012; Chan and Graham, 2004), which
infers the involvement of an unexpected regulation of the blood
clotting mechanism (Fig. 4A). In fact, NSAIDs including aspirin,
rofecoxib and celecoxib inhibit the action of cyclooxygenases,
which results in the production of thromboxane A2, a blood
coagulant in the platelets. Therefore, this cluster catalogues three
distinct administration patterns which can lead to gastrointestinal
and nervous system haemorrhages.
In cluster 29, extracted REACs were eye disorders such as “par-
tial vision loss”, “retinal structural change, deposit and degeneration”,
and “ocular haemorrhagic disorders”, which were associated with
DRUGs with diverse INDIs as follows. Type 1: Bevacizumab and
ranibizumab, monoclonal IgG1 antibody that inhibits the biologic
activity of human vascular endothelial growth factor (VEGF), were
used in the treatment of “retinal structural change, deposit and
degeneration”, “ocular vascular disorders”, and “choroid and vitreous
haemorrhages and vascular disorders”. Verteporﬁn also had these
three INDIs. Type 2: Sildenaﬁl is a vasoactive agent, which was
indicated in this cluster to treat “sexual arousal disorders”. Type
3: Interferon beta-1a was  used to treat “multiple scleroses acute
and progressive”. Type 4: Etanercept is a fusion protein, which
removes of pro-inﬂammatory cytokine tumor necrosis factor (TNF)
from circulation, resulting in relieves of severe rheumatoid arthri-
tis and severe plaque psoriasis as indicated in this cluster. In
this cluster, there is a number of overlaps in the REAC and INDI
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Fig. 4. Schematic view of possible mechanisms underlying medically similar REACs from DRUGs with several distinct types of INDIs. (A) Mechanisms for occurrences of
h er 29)
T
t
r
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iaemorrhages (Cluster 17). (B) Mechanisms for occurrences of eye disorders (Clust
able  1. Detailed descriptions of the mechanisms are found in the text.
erms in the HLT level. In fact, verteporﬁn, bevacizumab, and
anibizumab were used to treat structural alteration and haem-
rrhages in the eye, while these INDI terms were also reported as
EACs. This indicates an incomplete regulation of the drugs lead-
ng to the eye-related ADRs. Ocular adverse events in bevacizumab. (C) Mechanisms for the occurrences of movement disorders (Cluster 30). See also
and  ranibizumab have been discussed in van der Reis et al. (2011).
Additional remarks about this cluster are that it partly infers the
involvement of unexpected regulation in the formation and regu-
lation of the blood vessels. In addition, sildenaﬁl is a vasodilator,
whose drug actions are also known in the retina. These suggest the
S. Mizutani et al. / Computational Biology and Chemistry 50 (2014) 50–59 55
Fig. 5. Gender distributions of REACs by the same drugs in different clusters. Comparison of gender distributions in event reports from cluster 148 (red) and cluster 163
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rblue). Clusters 148 and 163 contained different REACs listed in the bottom table,
ontained female patients for both isotretinoin and etanercept, while cluster 163 c
ppearing in cluster 148. (For interpretation of the references to color in this ﬁgure
nvolvement of blood-related common mechanism in the occur-
ences of ocular haemorrhagic disorders caused by the different
rug administrations (Fig. 4B). In cluster 30, abnormal body move-
ent related ADRs were collected to associate with DRUGs of
oughly two INDIs. Type 1: Aripiprazole, haloperidol, quetiapine,
iprasidone, and risperidone, 5-HT and/or D2 receptor antago-
ists, showed similar INDI proﬁles. Ziprasidone and risperidone
re atypical antipsychotics indicated primarily for the treatment of
schizophrenia” and “bipolar disorders”. Aripiprazole and haloperi-
ol are also antipsychotics indicated for the two disorders, but
an be also applied in other psychoses. Quetiapine is a multi-
cting-receptor-targeting-antipsychotics (MARTA) used to treat
schizophrenia”. Type 2: Atomoxetine showed different INDI pro-
le. Atomoxetine is a selective norepinephrine reuptake inhibitor
NRI) (noradrenalin transporter inhibitor) which was only used in
he treatment of “attention deﬁcit hyperactivity disorders”. These
rugs all showed abnormal body movement related REACs such
s “dyskinesias”, “dystonias”, “altered body temperature”, “Parkinso-
ism”, “eyelid movement disorders” and “decreased physical activity
evels”. This suggests the two primary drug administrations respon-
ible for the occurrences of the altered body movements. Some
f the movement disorders such as “dyskinesias” have been sus-
ected to be caused by dopaminergic blockage (Mathews et al.,
005). Type 1 drugs inhibit dopamine receptor. Norepinephrine
ransporter is also involved in dopamine uptake in the prefrontal
ortex (Morón et al., 2002). Therefore, the dopamine blockage is
 possible common mechanism involved in the expression of the
ovement disorders extracted in this cluster (Fig. 4C).
.4.  Inter-cluster comparison of event reports by the patients’
hysiological backgroundsPer-drug  inter-cluster pairwise comparison of event reports
eveals interesting features of ADR incidence attributed to the
atients’ physiological backgrounds. In the total of 182 000 event
eports associated to the 163 clusters, the following number ofh were both reported as ADRs from isotretinoin and etanercept. Cluster 148 only
ed both female and male, which suggests female sex be a risk factor for the REACs
d, the reader is referred to the web version of this article.)
event  reports were provided with gender, age, and body weight
data in FAERS; 166 704 for gender, 80 013 for age, and 33 315 for
body weight. We examined differences in the physiological back-
grounds between populations of event reports from two different
clusters with exclusive groups of REACs, but same DRUG(s). The
total of 17 363 event report pairs spanning 152 drugs were tested
for the distribution differences. Statistical signiﬁcance in gender
distributions was  tested by the Fisher’s exact test, and those in age
and body weight distributions were tested by the Welch’s t-test.
As a result, 1606 event report pairs showed signiﬁcant difference
(p < 0.05) in gender distributions. These pairs were associated with
69 DRUGs. 2514 showed signiﬁcant difference (p < 0.05) in age dis-
tributions. These pairs were associated with 80 DRUGs. In addition,
707 pairs showed signiﬁcant differences (p < 0.05) in body weight
distributions. These pairs were associated with 49 DRUGs.
Here we  present examples of such event report pairs. Exam-
ples were selected from cases where the distribution differences
were observed in more than one drug in the associated cluster
pair, extending the discussion to which the patients’ physiolog-
ical backgrounds are important risk factors for the associated
REACs. Comparison of clusters 148 and 163 on either etanercept, an
antirheumatoid drug, or on isotretinoin, an acne agent, showed dif-
ferent gender distributions in event reports. For both of the drugs,
patients in cluster 148 were all female, whereas patients in cluster
163 were female and male (Fig. 5, top). In cluster 148, REACs con-
tained “vaginal and vulval infections and inﬂammations”, which is
consistent with the gender data. This cluster also contained other
infections such as “streptococcal infections”, “fungal infections”, and
“mass conditions” and “autoimmune disorders” (Fig. 5, bottom). This
indicates the increased risk of these REACs in female patients. Clus-
ter 163 contained REACs such as “neurologic visual problems”, “visual
disorders”, “cardiac signs and symptoms”, and “circulatory collapse
and shock”. In contrast to the case in cluster 148, REACs in clus-
ter 163 were less likely to be gender-speciﬁc. Etanercept, used to
treat rheumatoid arthropathies and psoriatic conditions, is known
to express infections, autoimmune disorders, and cardiac disorders
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Fig. 6. Age distributions of REACs by the same drugs in different clusters. Comparison of event reports from cluster 106 (red) and cluster 116 (blue) showed signiﬁcantly
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iifferent age distributions for interferon beta 1-a (p = 6.2E−10), and for levonorgest
t  can be inferred that middle-ages are risk factors for REACs in cluster 116. (For in
eb  version of this article.)
DailyMed). For isotretinoin infections and cardiovascular disor-
ers are known ADRs (DailyMed). Gender-related risk for the ADR
ncidences is not generally documented in public pharmaceutical
atabases. However, female sex has been suggested as a risk factor
n Hernández et al. (2013).
Comparison of clusters 106 and 116 on either interferon beta-
a, an anti-neoplastic, or on levonorgestrel, a contraceptive agent,
howed signiﬁcant difference in age distributions (Fig. 6, top).
ig. 7. Body-weight distributions of REACs by the same drugs in different clusters. Compar
ody  weight distributions for paroxetine (p = 1.6E−7), and for rofecoxib (p = 3.0E−3). Clus
ere  newborn infants, which implies the associated REACs are probably resulted in the p
n  this ﬁgure legend, the reader is referred to the web  version of this article.) 2.6E−6). Clusters 106 and 116 showed unrelated REACs listed in the bottom table.
tation of the references to color in this ﬁgure legend, the reader is referred to the
Patients  of both drugs in cluster 116 were all female, consistent with
that the extracted REACs were benign and malignant neoplasms in
the female reproductive systems (Fig. 6, bottom), and mostly at the
middle-age from around 30 to 50 years old (for interferon beta-1a)
or around 30 to 55 years old (for levonorgestrel). Interferon-beta is
used for the treatment of relapsing and remitting multiple sclerosis.
Levonorgestrel is used for contraception, control of menstrual dis-
orders, and treatment of endometriosis. Risk of ovarian and breast
ison of event reports from cluster 108 (red) and cluster 156 (blue) showed different
ter 49 and 163 contained different REACs. Note paroxetine patients in cluster 156
aroxetine exposure in their mothers. (For interpretation of the references to color
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ancers has been documented for patients who currently have
hese diseases in DailyMed, and for postmenopausal women  (Grady
t al., 1995; Chlebowski et al., 2003; Anderson et al., 2004; Stefanick
t al., 2006). Our result adds a supporting evidence to suggest rela-
ively higher risk of uterine and ovarian neoplasms in middle-aged
omen in the use of either interferon beta-1a or levonorgestrel.
n cluster 106, patients of interferon beta-1a showed a wider age
ange (signiﬁcant age difference with p = 6.2E−10), and patients
n levonorgestrel were younger (p = 2.6E−6), compared to the age
istribution in cluster 116. In cluster 106, REACs were mostly
ervous system disorders such as “disturbances in consciousness”
nd “neurological signs and symptoms”, and psychiatric disorders
uch as “dyssomnias”, “anxiety symptoms”, “emotional and mood
isturbances”, “increased physical activity levels”, “ﬂuctuating mood
ymptoms”, and “mood alterations with manic symptoms” (Fig. 6, bot-
om). In our result, younger levonorgestrel patients showed these
EACs. Interferon beta-1a is reported to express psychiatric dis-
rders (DailyMed), which was, according to our result, less likely
o be age-related. However, our result indicates levonorgestrel use
n younger ages seemed to be related to the occurrences of these
EACs.
Comparison of cluster 108 and 156 revealed the difference in
he body weight distributions of the event reports on paroxet-
ne, an anti-depressant, or rofecoxib, an anti-inﬂammatory agent
Fig. 7, top). For paroxetine, patients who reported the REACs in
luster 156 were mostly newborn infants because associated body
eights were all less than 5 kg, whereas patients in cluster 108
ere mostly adults (p = 1.6E−7). Cluster 108 lists REACs such as
cardiac signs and symptoms” and “circulatory collapse and shock”.
n cluster 156, REACs were “non-site speciﬁc injuries”, “inner-ear
igns and symptoms”, “vertigos”, “myocardial disorders”, and “umbil-
cal hernias” (Fig. 7, bottom). This indicates that the pregnancy is an
mportant risk factor for the paroxetine toxicity in the fetus. Indeed,
he risk of cardiovascular defects in infants has been reported as
 result of paroxetine exposure in pregnant women  (DailyMed).
or rofecoxib, patients in cluster 108 showed relatively lower body
eights than those in cluster 156 (p = 3.0E−3). The effects of body
eights in the incidence of different REACs remains unknown, but
ur result might indicate body weight as a factor to differentiate
he REACs in cluster 108 and 156.
. Conclusion
In this paper, we identiﬁed clusters of ADRs with coherent
vent frequencies, by applying a biclustering method on the FDA’s
dverse event data. Then we catalogued drug indications that
ere associated to the ADRs, and discussed why  the drugs with
ifferent indications all showed high occurrences of the ADRs. Cat-
loguing drug indication proﬁles and linking them to medically
imilar ADRs may  help us to infer common mechanisms underlying
heir occurrences. The clusters partly explained the drug-induced
lterations common to the actions of drugs with different adminis-
rations at physiological or molecular levels. Pairwise comparison
f clusters delineated how patients’ conditions affect the inci-
ence of adverse reactions, demonstrating that extracting side
ffect information in drug package inserts is limited in this con-
ext.
Possible factors that are involved in the occurrences of adverse
rug reactions are the off-targets, indigenous molecules that may
e targeted by the drugs because of the drugs’ polypharmacology
Campillos et al., 2008; Kuhn et al., 2013). Although systematic
nderstanding of the molecular mechanisms remains to be further
tudied, our results will provide a picture of the overall patterns
f drug administrations which lead to medically similar adverse
eactions.y and Chemistry 50 (2014) 50–59 57
4. Materials and methods
4.1.  Adverse drug reaction and drug data sets
The total of 1 670 724 event reports submitted from 2004
to the third quarter of 2012 were downloaded from the FDA
Adverse Event Reporting Systems (FAERS) (http://www.fda.gov/
Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/
AdverseDrugEffects/default.htm).  These event reports contained
13 599 ADRs and associated 4939 drugs in total. Note that we
only used event reports listing exactly one non-concomitant drug
whose name is regularized by FDA. In addition, event reports that
contained the same symptoms both in ADRs (REAC ﬁles in FAERS)
and in drug indications (INDI ﬁles in FAERS) were removed.
ADR  terms in the FAERS are coded in the Preferred Terms
(PT) of the Medical Dictionary for Regulatory Activities (MedDRA)
Terminology. MedDRA is the international medical terminology
developed under the auspices of the International Conference on
Harmonisation (ICH) of Technical Requirements for Registration of
Pharmaceuticals for Human Use. It provides a classiﬁcation of ADRs
in ﬁve hierarchical levels, “System Organ Class (SOC)”, “High Level
Group Terms (HLGT)”, “High Level Terms (HLT)”, “Preferred Terms
(PT)”, and “Lowest Level Terms (LLT)”. Since ADRs are hierarchically
annotated by the MedDRA classiﬁcation, we  ﬁrst converted ADR
terms from PT level to HLT level. The ADRs that were classiﬁed
in the following SOC categories, “investigations”, “social circum-
stances”, and “surgery and medical procedures” were removed from
the dataset, because these events are less likely to be the ADRs
of drugs. This yielded 1317 ADR terms. 1909 drugs in the FAERS
dataset were linked to the corresponding 1374 entries in the KEGG
DRUG database (Kanehisa et al., 2012), which are regulated by
KEGG identiﬁcation numbers (referred to as D numbers). As a result,
1317 reactions and 1374 drugs were used to construct a frequency
matrix which contains 425 273 adverse event reports in total. Each
row represents an ADR and each column represents a drug.
4.2.  Finding clusters of REACs and DRUGs
In order to ﬁnd biclusters of REACs and DRUGs, we performed
a biclustering on the constructed 1374 reactions vs. 1317 drugs
matrix, using an algorithm called the Iterative Signature Algorithm
(ISA) implemented in the R package, isa2 (Ihmels et al., 2004).
The advantage of the ISA algorithm among others is that it can be
applied to a large, noisy input matrix (Ihmels et al., 2004; Bergmann
et al., 2003), and it allows overlaps between biclusters. It detects the
subsets of rows and columns whose values are consistently higher
than all other rows and columns by iteratively reﬁning the subsets
of rows and columns which ﬁnally reach given thresholds. The fol-
lowing two  steps were performed iteratively. First, given a set of
REACs, each DRUG was tested if the absolute value of the average
frequency over the given set of ADRs exceeded a column thresh-
old (thr.col). If it exceeded thr.col, it was  selected in a set of DRUGs,
and was used for the second step. Second, with the set of DRUGs
ﬁxed, each REAC was  tested if the absolute value of the average fre-
quency over the set of DRUGs exceeded a row threshold (thr.row).
If it exceeded the thr.row, then it was selected in a new REAC set,
which was  used for the next iteration. The row and column thresh-
olds controlled the stringency of the row sets and column sets,
respectively. Especially, if the data matrix was normalized row-
wise, thr.row value was  equivalent to the degree of how much the
frequency averaged over the selected rows exceeded the average
frequency of all rows in the data. ISA started with a set of random
seeds (randomly picks up REACs), and proceeded the above two
steps iteratively until a convergence was  reached, i.e., the selected
set of rows and columns in the current iteration became equal to the
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et obtained from the previous iteration. The convergent subsets
ere referred to as “clusters” (or “biclusters”) in this study.
The  original frequency matrix was normalized row wise (for
ach REAC). The threshold values for REACs (thr.row) were set in
 range of 1 to 5 in increments of 0.5. Columns were not normal-
zed and therefore thought to show a wider value range. Hence,
he threshold values for DRUGs (thr.col) were set in a broader
ange, which is from 2 to 20 in increments of 2. For each combina-
ion from different thr.row and thr.col, 2000 clusters were initially
etected, that were converged from 100 random starting points
cross rows and columns. The initial 2000 clusters were ﬁltered
or highly robust ones following the developer’s recommendation.
hr.rows in a range from 3 to 5 and thr.cols in a range from 2 to
0 were determined to be optimal, so that clusters were stringent
nough within the bounds of retaining as high number of REACs and
RUGs as possible (Fig. S1). Next, clusters obtained from the differ-
nt threshold values were merged. Since the resulting clusters were
till highly redundant, the ISA redundancy removal function was
pplied to reduce the number of very similar clusters using simi-
arity score 0.8 (Fig. S2). Finally, the clusters whose REAC and DRUG
embers were all included in any other clusters were discarded.
.3.  Referring for known ADRs
In the original FAERS matrix, out of 1374 drugs in D numbers,
092 were reported in the SIDER database for 1053 ADRs in the
edDRA HLT terms. Likewise, in the extracted 163 clusters, which
ontained 240 drugs and 691 reactions, 203 drugs were listed in
he SIDER database for 544 ADRs.
.4. Drug indications, gender, age, and body weight data
In  order to characterize the obtained clusters of REACs and
RUGs, we used drug indication information available for each
dverse event report in the FAERS dataset. Out of 182 000 event
eports in 163 clusters, 95 888 reports were available with indica-
ion data from FAERS indication (INDI) ﬁles. Since the indication
erms are coded in the MedDRA PT terms, they were converted to
he MedDRA HLT terms, which resulted in the total of 889 indica-
ions in the MedDRA HLT terms. For each of the DRUGs in a cluster,
e constructed a proﬁle of drug indications (INDI proﬁles), where
he number of corresponding event reports was counted for each
f the INDIs. Then, we compared all DRUG pairs using the INDI pro-
les. For each drug pair we calculated the absolute value of the
earson’s correlation coefﬁcient between the two  corresponding
NDI proﬁles, and then took the average over all DRUG pairs within
he cluster.
For  each adverse event report, patients’ physiological condi-
ions data such as gender, age and body weight were obtained
rom FAERS demographic (DEMO) ﬁles. In the total of 182 000 event
eports associated to the 163 clusters, 166 704 event reports, 80 013
vent reports and 33 315 event reports were provided with gender,
ge, and weight data, respectively.
.5. Medical characterization of REACs using Gini coefﬁcient
For  each of the 163 clusters, we gave a hierarchical classiﬁca-
ion of the REACs, and measured their classiﬁcation variations by
omputing the Gini coefﬁcient. The Gini coefﬁcient measures the
nequality among values of a frequency distribution across classi-
cation. If all members in a group are classiﬁed in one category,
ts Gini coefﬁcient is one, and this group has no variation. If every
ember in a group is equally frequently distributed across different
ategories, the Gini coefﬁcient is zero, and this group has a maximal
ariation.y and Chemistry 50 (2014) 50–59
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